免疫疗法治疗慢性乙肝病毒感染者疗效观察  

Therapeutic effect of levamisole plus HBV vaccine and dipyridamole on patients chronically infected by HBV with precore mutation

作　　者：罗筱莲 王燕[2] 田庚善[3] 傅希贤[3] 王永怡[4] 魏来[2] 陈捷[5] 苏盛[5] 范公忍[6] 

机构地区：[1]芜湖市第三人民医院,241000 [2]北京大学附属人民医院肝病研究所 [3]北京大学第一医院感染疾病科 [4]解放军第三○二医院 [5]北京地坛医院 [6]北京军区总医院检验科

出　　处：《中华实验和临床病毒学杂志》2004年第3期284-286,共3页Chinese Journal of Experimental and Clinical Virology

摘　　要：目的　探讨抗HBe阳性的HBV慢性感染者前C区变异株的发生率及治疗方法。方法　选择抗HBe阳性的HBV慢性感染者 ,应用DNA序列分析方法检测其前C区的变异的发生率 ,然后用免疫疗法 (左旋咪唑搽剂 +乙肝疫苗 +潘生丁 )治疗 ,观察其对HBV前C区变异株患者的疗效 ,并以HBeAg阳性患者为对照。结果　 (1)抗HBe阳性的HBV慢性感染者前C区变异发生率为 10 12 ;10例均为A1896终止变异 ,其中 5例与野生株混合 ,6例伴BCP变异。 (2 )本试验的免疫疗法对前C区变异株的疗效 (5 7)优于HBeAg阳性者 (2 11)的疗效。结论　 (1)本研究对象中抗HBe阳性的HBV慢性感染者前C区变异发生率较高 ;(2 )本研究所试用的免疫疗法对前C区变异株的疗效优于对HBeAg阳性者的疗效。但均因例数太少难于肯定 ,需进行更大样本的研究。Objective To evaluate the incidence of precore mutation in HBeAg negative HBV infected patients and the therapeutic effect of the immune therapy (levamisole + HBV vaccine + dipyridamole) on patients chronically infected by HBV with precore mutation Methods The percore region of HBV from the HBeAg (-) chronic hepatitis patients was sequenced and the patients suffered from HBV with precore mutation were treated with immune therapy Results The precore mutation rate was 10/12 The therapeutic effect of the immune therapy on the precore mutation patients (5/7) was better than that on the HBsAg(+),HBeAg(+) patients (2/11),P<005 Conclusion The percore mutation rate was quite high in the HBsAg(+),HBeAg(-) patients we studiedThe immune-therapy has some therapeutic effects on the patients with precore mutationBut the number of cases was too small, further study is needed

关 键 词：前C区变异 免疫疗法 治疗 HBV慢性感染 抗HBE阳性 发生率 HBEAG阳性 变异株 试验 选择 

分 类 号：R512.62[医药卫生—内科学] R759.1[医药卫生—临床医学]